News & Videos - SHIRE PLC ADS

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Shire plc 17-Dec-2018 / 13:48 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser : The Vanguard Group, Inc....

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Shire plc 16-Nov-2018 / 15:02 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser : The Vanguard Group, Inc....

NEW YORK, NY / ACCESSWIRE / August 3, 2017 / Shire PLC (NASDAQ: SHPG ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 3, 2017 at 9:00 AM Eastern Time. To listen to the event live - visit https://www.investornetwork.com/company/22908 . Replay Information The replay will be available online at https://www.investornetwork.com/company/22908 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Shire plc (SHPG) PR Newswire NEW YORK, June 8, 2017 NEW YORK , June 8, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shire plc ("Shire" or the "Company") (NASDAQ: SHPG). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/shpg . The...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shire plc - SHPG PR Newswire NEW YORK, June 7, 2017 NEW YORK , June 7, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Shire plc ("Shire" or the "Company") (NYSE: SHPG). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The investigation concerns whether Shire and certain of its officers and/or directors have...

SHIRE PLC - Director/PDMR Shareholding PR Newswire London, June 1 Director/PDMR Shareholding June 1, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) Notification of transactions by person discharging managerial responsibilities 1. Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated them (“PCA”) a) Name Kim Stratton 2. Reason for the notification a) Position / status Head of International Commercial - PDMR b) Initial...

Se ha presentado la primera alianza público-privada de Acción Humanitaria creada en España. La Alianza Shire nace con el objetivo de dar acceso a energía ......

Shire to Participate at the Jefferies Healthcare Conference PR Newswire LEXINGTON, Massachusetts, May 25, 2017 LEXINGTON, Massachusetts , May 25, 2017 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will participate at the Jefferies Healthcare Conference in New York City , NY on Thursday, June 8, 2017 at 3:00 PM EDT ( 20:00 BST ). A live audio webcast will be available on the Presentations and Webcasts section of Shire's Investor...

SHIRE PLC - Blocklisting - Interim Review PR Newswire London, May 23 BLOCK LISTING SIX MONTHLY RETURN May 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) Name of applicant : Shire plc Name of scheme: Shire Sharesave Scheme Period of return: From: November 23, 2016 To: May 22, 2017 Balance of unallotted securities under scheme(s) from previous return: 184,611 Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):...

The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis PR Newswire DUBLIN, May 18, 2017 DUBLIN , May 18, 2017 /PRNewswire/ -- Study met primary endpoint demonstrating significantly greater remission rates in patients receiving anti-MAdCAM antibody (SHP647) compared to placebo in three of four tested dose groups First study to investigate the potential role of...

SHIRE PLC - Positive lanadelumab topline Phase 3 results PR Newswire London, May 18 Shire’s Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial Significant reduction in monthly Hereditary Angioedema (HAE) attack rate with infrequent subcutaneous administration Data to serve as basis for U.S. BLA filing expected in Q4 2017 to Q1 2018 Shire to host Investor Call today at 10 a.m. ET ; details below...

Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial PR Newswire LEXINGTON, Massachusetts, May 18, 2017 LEXINGTON, Massachusetts , May 18, 2017 /PRNewswire/ -- Significant reduction in monthly Hereditary Angioedema (HAE) attack rate with infrequent subcutaneous administration Data to serve as basis for U . S . BLA filing expected in Q4 2017 to Q1 2018 Shire to host Investor Call today at 10 a.m. ET;...

Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psychiatric Association Latest Research Supports Greater Understanding of the Evolving Needs of Adults with ADHD PR Newswire LEXINGTON, Massachusetts, May 16, 2017 LEXINGTON, Massachusetts , May 16, 2017 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) will present research on the evolving needs of adults living with Attention-Deficit/Hyperactivity Disorder (ADHD) at the upcoming 170 th Annual...

SHIRE PLC - Director/PDMR Shareholding PR Newswire London, May 3 Director/PDMR Shareholding May 3, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) Notification of transactions by person discharging managerial responsibilities 1. Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated them (“PCA”) a) Name Matt Walker 2. Reason for the notification a) Position / status Head of Technical Operations – PDMR b) Initial notification /...

SHIRE PLC - 1st Quarter Results PR Newswire London, May 2 Shire delivers strong Q1 2017 revenue growth while advancing late-stage pipeline Commercial execution, efficiency improvements, and debt pay-down remain top priorities May 2, 2017 – Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months ended March 31, 2017 . Flemming Ornskov, M.D., M.P.H., Shire Chief Executive Officer, commented: "In the first quarter we delivered strong top-line growth with...

Shire Delivers Strong Q1 2017 Revenue Growth While Advancing Late-stage Pipeline PR Newswire DUBLIN, May 2, 2017 DUBLIN , May 2, 2017 /PRNewswire/ -- Commercial execution, efficiency improvements, and debt pay-down remain top priorities Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months ended March 31, 2017 . Flemming Ornskov, M.D., M.P.H., Shire Chief Executive Officer, commented: "In the first quarter we delivered strong top-line growth with quarterly...

Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications PR Newswire LEXINGTON, Massachusetts and DURHAM, North Carolina, May 1, 2017 LEXINGTON, Massachusetts and DURHAM, North Carolina , May 1, 2017 /PRNewswire/ -- Demonstrat e s o ngoing c ommitment to i nnovation in ophthalmics for Shire P-321 is a P hase 2 investigational topical treatment for dry eye disease Shire plc (LSE: SHP, NASDAQ: SHPG) and Parion Sciences, Inc. today announced...

Shire Granted EU Conditional Marketing Authorisation for Natpar[®▼] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism PR Newswire ZUG, Switzerland, April 26, 2017 ZUG, Switzerland , April 26, 2017 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission (EC) has granted Conditional Marketing Authorisation...

SHIRE PLC - Result of AGM PR Newswire London, April 25 Result of the 2017 Annual General Meeting April 25, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that, at its Annual General Meeting held at The Merrion Hotel, Upper Merrion Street, Dublin 2, Ireland at 2.45pm today, all resolutions contained in the Notice of Meeting were decided by poll vote. The results of the poll are as follows: Resolutions For (including discretionary votes) % Against % Votes cast as a % of...

Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI) Shire launches campaign to raise global awareness during World PI Week PR Newswire ZUG, Switzerland, April 24, 2017 ZUG, Switzerland , April 24, 2017 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, is launching #PIPostsThanks, a social campaign to spotlight the unsung heroes who make a difference in the lives of people living with primary immunodeficiency...